Transgenic Models
Transgenic Models - Related Videos
13:59
Assaying β-amyloid Toxicity using a Transgenic C. elegans Model
0 Views •
Cited by 76 •
2010
The intensely studied nematode worm Caenorhabditis elegans can be transgenically engineered to express the human β-amyloid peptide (Aβ). Induced expression of Aβ in C. elegans muscle leads to a rapid, reproducible paralysis phenotype that can be used to monitor treatments that modulate Aβ toxicity.
02:16
Differentiating Non-Transgenic and Transgenic Human Pluripotent Stem Cells into Neural Progenitor Cells
0 Views •
2025
This video demonstrates the generation of neural progenitor cells from non-transgenic and transgenic human pluripotent stem cells (hPSCs). hPSCs are differentiated into neural progenitor cells using a neuronal differentiation medium. While differentiation is induced in non-transgenic cells using small molecules, the transgenic hPSCs are differentiated by adding an antibiotic that induces the promoter for a neuronal differentiation-specific transcription factor.
12:09
Generation of Stable Transgenic C. elegans Using Microinjection
0 Views •
Cited by 93 •
2008
This video demonstrates the technique of microinjection into the gonad of C. elegans to create transgenic animals.
04:03
Triggering and Monitoring Heat-Induced Seizures in a Transgenic Mouse Model
0 Views •
2025
This video demonstrates the procedure to induce heat-induced seizures in a transgenic mouse with epilepsy-related gene mutations by gradually increasing body temperature in a controlled chamber. This protocol is used to study seizure mechanisms and potential therapies for epilepsy.
17:39
Microinjection of A. aegypti Embryos to Obtain Transgenic Mosquitoes
0 Views •
Cited by 56 •
2007
In this video, Nijole Jasinskiene demonstrates the methodology employed to generate transgenic Aedes aegypti mosquitoes, which are vectors for dengue fever. The techniques for correctly preparing microinjection needles, dessicating embryos, and performing microinjection are demonstrated.
FAQs
An introduced DNA sequence can become integrated into the genome and direct production of a defined protein. That protein may alter a biological pathway, allowing researchers to connect gene activity with cellular or disease-related changes. The resulting organism provides a controlled experimental setting for examining how a specific genetic alteration influences biological function.
Conventional insertion places a selected DNA sequence into embryonic cells or embryos for genomic integration, whereas targeted genome editing is designed to control where the genetic change occurs. This greater control can help researchers create models with a more precisely defined alteration, improving the ability to relate a gene or pathway to a disease feature.
Its value depends on whether the engineered organism reproduces relevant features of the human condition or changes a biological pathway of interest. When a model reflects aspects of cancer, diabetes, neurodegeneration, or an inherited disorder, researchers can investigate disease mechanisms in an experimental system and assess how potential interventions affect those features.
Researchers can introduce a selected sequence and observe the resulting protein production or pathway alteration in the organism. Comparing these biological changes with disease-related features helps reveal how gene activity contributes to pathology. This approach is useful when the aim is to move from a genetic observation toward a mechanistic explanation of disease.
The process begins by selecting the DNA sequence linked to the biological question. Researchers then introduce it into embryonic cells or embryos, where it can integrate into the genome and produce the intended protein or pathway change. Modern workflows may instead apply targeted genome editing when more precise genetic control is needed.
These models are used to study disease mechanisms and to examine potential drugs, gene therapies, and treatment safety before clinical studies. Their applications include cancer, diabetes, neurodegeneration, and inherited disorders. By placing a genetic change within a living experimental system, they support evaluation of how candidate interventions relate to disease-associated biology.
A transgenic model can show whether a genetic alteration produces a defined protein, changes a biological pathway, or reproduces selected features of disease. It can also provide an experimental setting for examining responses to candidate drugs or gene therapies and for evaluating treatment safety, helping inform decisions about progression toward clinical research.